OTHER MICROBIOME INDICATIONS

OTHER MICROBIOME INDICATIONS

C. Difficile infection (CDI) is the first clinical candidate in our microbiome program, however we are rapidly expanding our efforts to address some of the many emerging health conditions where there is a significant scientific and clinical rationale for the role of the gut microbiome along with high unmet medical need.

Our integrated platform for strain selection, cGMP manufacturing and development and targeted Gemicel® delivery allow Assembly to rapidly and efficiently address additional therapeutic indications, both on our own and with a variety of partners.

ASMB MICROBIOME PLATFORM FOR THERAPEUTIC AREA EXPANSION

Infectious Disease
  • CDI (FIRST INDICATION)
  • Antibiotic resistant organisms
Gastro
  • IBD
  • Crohn's
  • Ulcerative
    Colitis
  • IBS
Metabolic Disease
  • Obesity
  • Diabetes/Prediabetes
CNS
  • Psychiatric
  • Autism
Oncology
  • Colorectal cancer
  • Oncology